Clinical Trials

Clinical Trial Detail

Return to search results.

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma

Complete title: A Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory B Cell Malignancies

Research Study Number       2669.00
    
Principal Investigator       Bill Bensinger, MD
    
Phase       I/II

Look up trial at NIH

Research Study Description

The purpose of this study is to determine how well SNS01-T is tolerated by relapsed or refractory multiple myeloma, mantle cell lymphoma or diffuse large B cell lymphoma patients when given by intravenous infusion at various doses.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.



Research Study Number       2669.00
    
Contact       Seattle Cancer Care Alliance Intake Office
    
Telephone       800-804-8824 / 206-288-1024
    
   

Keywords
Hematologic Malignancies; Lymphoma; Multiple Myeloma (MM)

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.